Strategic Alliances and Collaborations
- Moderna Therapeutics in strategic transactions with Merck, Alexion Pharmaceuticals and AstraZeneca with total upfront deal value in excess of $650 million, plus downstream payments; most recently, in its strategic collaboration with Merck for mRNA-based personalized cancer vaccines, with an upfront payment of $200 million
- Blueprint Medicine in its worldwide collaboration with Roche for up to five small molecule kinase therapeutics for cancer immunotherapy; upfront of $45 million with total deal value of up to $965 million
- ImmuNext in its exclusive, worldwide license with Sanofi to develop and commercialize a CD40L monoclonal antibody for use in autoimmune diseases, with potential deal value of up to $500 million, plus royalties
- BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks
- Teva in its license agreement with Heptares to develop and commercialize novel, small-molecule calcitonin gene-related peptide antagonists discovered by Heptares, valued up to $410 million, plus royalties
- Cephalon in its exclusive license agreement with Eagle Pharmaceuticals with a total deal value in excess of $120 million, plus royalties
- Surface Oncology in its strategic collaboration with Novartis to develop immunotherapeutics; up to $170 million in near-term cash payments, plus milestones and royalties
- Unum Therapeutics in its strategic collaboration and license agreement with Seattle Genetics to develop and commercialize ACTR therapies for cancer, with a total potential deal value of over $640 million, plus royalties
- Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease, with a total potential deal value up to $2.6 billion in milestones, plus royalties
- Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
M&A
- Nimbus in its sale of Nimbus Apollo and its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead Sciences for $400 million and up to an additional $800 million in development milestone payments
- Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion
- F-star Alpha in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
- TARIS Biomedical in the sale of its lead product LiRIS to Allergan for a total potential deal value in excess of $580 million
- ZOLL Medical in its sale to Asahi Kasei for $2.2 billion
